SFX by Ex Libris Inc.

Title:	Progressive degeneration of human neural stem cells caused by pathogenic LRRK2
Source:	Nature [0028-0836] Liu, G H yr:2012

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Nichols, Dario J. "14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization." Biochemical journal 430.3 (2010): 393-404.
description	2.	Liu Z, W.W. u. "A Drosophila model for LRRK2-linked parkinsonism." Proceedings of the National Academy of Sciences of the United States of America 105.7 (2008): 2693-8.
description	3.	Yun, H. "Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein." Bioorganic and medicinal chemistry letters 21.10 (2011): 2953-2957.
description	4.	Anonymous. Age and ageing 27 (1998).
description	5.	Nguyen, Ha N. "LRRK2 mutant iPSC-derived da neurons demonstrate increased susceptibility to oxidative stress." Cell stem cell 8.3 (2011): 267-280.
description	6.	Seibler, P. "Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells." The Journal of neuroscience 31.16 (2011): 5970-5976.
description	7.	McNabney, M. "The "continuum of care" for older adults: design and evaluation of an educational series." Journal of the American Geriatrics Society 57.6 (2009): 1088-1095.
description	8.	Lee, Sung Bae B. "Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila." Biochemical and biophysical research communications 358.2 (2007): 534-9.
description	9.	Wernig, M. "Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease." Proceedings of the National Academy of Sciences of the United States of America 105.15 (2008): 5856-61.
description	10.	Chochinov,, Harvey M., Harvey M. "End-of-Life Care and the Elderly." The Psychiatric times 25.14 (2008): 19-25.
description	11.	Rautio, J. "Inhibitors of LRRK2 Kinase Activity To Probe the Treatment Option in Parkinson's Disease." Journal of medicinal chemistry 55.22 (2012): 9414-9415.
description	12.	Kramer, T. "Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models." ACS chemical neuroscience 3.3 (2012): 151-160.
description	13.	Cooper, O. "Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid." Molecular and cellular neurosciences 45.3 (2010): 258-266.
description	14.	Slone, Sunny R. "Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins." Neurobiology of disease 79 (2015): 1-13.
description	15.	Deng, X. "Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011)." Expert opinion on therapeutic patents 22.12 (2012): 1415-1426.
description	16.	Cöl Arslan, S. "The Prevalence of TNFα-Induced Necrosis over Apoptosis Is Determined by TAK1-RIP1 Interplay." PLoS ONE 6.10 (2011).
description	17.	Bardien, S. "Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease." Parkinsonism & related disorders 17.7 (2011): 501-508.
description	18.	Morris, M. "The many faces of tau." Neuron 70.3 (2011): 410-426.
description	19.	Nemati, S. "Long-term Self-Renewable Feeder-Free Human Induced Pluripotent Stem Cell-derived Neural Progenitors." Stem cells and development 20.3 (2010): 503-514.
description	20.	Nichols, M. "Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization." Biochemical journal 430.3 (2010): 405-413.